Endocrine complications in the treatment of autoimmune diseases by high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
AbstractHigh-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-HSCT) is a promising direction in the treatment of autoimmune diseases, including autoimmune endocrine pathology. Due to the increase in the number of performed HDIT-HSCT, there is a growing interest in the impact of the procedure on the endocrine system in the therapeutic community.
The purpose of the review was to analyze scientific publications on the topic of endocrine complications of HDIT-HSCT in autoimmune diseases in order to form ideas about secondary pathology on the part of the endocrine system. Currently, the negative effect of this method of treatment on the reproductive function of men and women, as well as on the development of autoimmune thyroid diseases, has been shown.
Keywords:HDIT-HSCT; endocrinopathy; thyroid function; hypogonadism; fertility
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Chernaya M.E., Orlovskaya A.D., Polushin A.Yu., Zalyalov Yu.R., Lisker A.V., Volkova A.R., Kulagin A.D., Khalimov Yu.Sh. Endocrine complications in the treatment of autoimmune diseases by high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (2): 69–77. DOI: https://doi.org/10.33029/2304-9529-2023-12-2-69-77 (in Russian)
References
1. Wang L., Wang F.S., Gershwin M.E. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015; 278 (4): 369–95.
2. Biondi B., Kahaly G.J., Robertson R.P. Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev. 2018; 40 (3): 789–824.
3. Cojocaru M., et al. Multiple autoimmune syndrome. Maedica (Bucur.). 2010; 5 (2): 132–4.
4. Nuralieva N.F., Yukina M. Yu., Troshina E.A. Basic immunopathogenic mechanisms of autoimmune thyroid disorders and type 1 diabetes mellitus. Doctor.Ru. 2019; 4 (159): 49–53. (in Russian)
5. Smilek D.E., Ehlers M.R., Nepom G.T. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech. 2014; 7 (5): 503–13.
6. Fassas A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997; 20: 631–8.
7. Gavriilaki M., et al. Autologous hematopoietic cell transplantation in multiple sclerosis: changing paradigms in the era of novel agents. Stem Cells Int. 2019; 2019: 5840286.
8. Alexander T., Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2022; 57 (7): 1055–62.
9. Sharrack B., et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020; 55 (2): 283–306.
10. Swart J.F., et al. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol. 2017; 13 (4): 244–56.
11. Polushin A. Yu., Zalyalov Yu.R., Totolyan N.A., Kulagin A.D., Skoromets A.A. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: a modern view of the method (review of literature). Uchenye zapiski Pervogo Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta imeni akademika I.P. Pavlova [Scientific Notes of the First Saint Petersburg State Medical University named after Academician I.P. Pavlov]. 2022; 28 (4): 9–21. (in Russian
12. Snowden J.A., et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2012; 47 (6): 770–90.
13. Polushin A. Yu. Zalyalov Yu.R., Totolyan N.A., Kulagin A.D., Skoromets A.A., et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: approaches to risk management. Annaly klinicheskoy i eksperimental’noy nevrologii [Annals of Clinical and Experimental Neurology]. 2022; 16 (3): 53–64. (in Russian)
14. Orio F., et al. Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells. Sci World J. 2014; 2014: 282147.
15. Milroy C.L., Jones K.P. Gynecologic care in hematopoietic stem cell transplant patients: a review. Obstet Gynecol Surv. 2010; 65 (10): 668–79.
16. Desai M.K., Brinton R.D. Autoimmune disease in women: endocrine transition and risk across the lifespan. Front Endocrinol. (Lausanne). 2019; 10: 265.
17. Moulton V.R. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018; 9: 2279.
18. Buyon J.P., Petri M.A., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005; 142 (12 pt 1): 953–62.
19. Holroyd C.R., Edwards C.J. The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus. Climacteric. 2009; 12 (5): 378–86.
20. de Paoli M., Werstuck G.H. Role of estrogen in type 1 and type 2 diabetes mellitus: a review of clinical and preclinical data. Can J Diabetes. 2020; 44 (5): 448–52.
21. Mauvais-Jarvis F. Are estrogens promoting immune modulation and islet protection in type 1 diabetes? J Diabetes Complications. 2017; 31 (11): 1563–4.
22. Maciejewska M., Snarski E., Wiktor-Jędrzejczak W. A preliminary online study on menstruation recovery in women after autologous hematopoietic stem cell transplant for autoimmune diseases. Exp Clin Transplant. 2016; 14 (6): 665–9.
23. Snarski E., Snowden J.A., Oliveira M.C., Simoes B., Badoglio M., Carlson K., et al. Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplant. 2015; 50 (2): 216–20.
24. Kvistad S.A.S., Lehmann A.K., Trovik L.H., et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Mult Scler. 2020; 26 (14): 1889–97.
25. Polushin A. Yu., Zalyalov Yu.R., Gavrilenko A.N., Tsynchenko A.A., Lopatina E.I., Skiba I.B., et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: preliminary clinical results of approbation of the method. Rossiyskiy nevrologicheskiy zhurnal [Russian Neurological Journal]. 2022; 27 (5): 25–35. (in Russian)
26. Dooley M.A., Nair R. Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat Clin Pract Rheumatol. 2008; 4 (5): 250–7.
27. Ben-Aharon I., Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? 2012; 144 (2): 153–63.
28. Arecco L., Ruelle T., Martelli V., et al. How to protect ovarian function before and during chemotherapy? J Clin Med. 2021; 10 (18): 4192.
29. Gu B., Miao H., Zhang J., et al. Clinical benefits of autologous haematopoietic stem cell transplantation in type 1 diabetes patients. Diabetes Metab. 2018; 44 (4): 341–5.
30. Voltarelli J.C., Couri C.E., Stracieri A.B., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007; 297 (14): 1568–76.
31. Leal A.M.O., Oliveira M.C., Couri C.E.B., et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT. 32. Bone Marrow Transplant. 2012; 47 (3): 467–8.
33. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 301 (15): 1573–9.
34. Snowden J.A., Saccardi R., Allez M., et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2012; 47 (6): 770–90.
35. Daikeler T., Labopin M., Di Gioia M., et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011; 118 (6): 1693–8.
36. Ragusa F., Fallahi P., Elia G., Gonnella D., Paparo S.R., Giusti C., et al. Hashimotos’ thyroiditis: epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab. 2019; 33 (6): 101367.
37. Burt R.K., Muraro P.AS., Farge D., et al. New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant. 2021; 56 (7): 1509–17.
38. Burt R.K., Han X., Quigley K., Helenowski I.B., Balabanov R. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. J Neurol. 2022; 269 (5): 2513–26.
39. Guillaume-Jugnot P., Badoglio M., Labopin M., Terriou L., Yakoub-Agha I., Martin T., et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clin Rheumatol. 2019; 38 (5): 1501–11.
40. Bar M., Ott S.M., Lewiecki E.M., Sarafoglou K., Wu J.Y., Thompson M.J., et al. Bone health management after hematopoietic cell transplantation: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020; 26 (10): 1784–802.
41. Kitaeva Y.S., Praskurnichiy E.A. Predictors of bone mineral density reduction in patients with Hodgkin’s lymphoma associated with pathogenetic therapy. Arkhiv vnutrenney meditsiny [Archives of Internal Medicine]. 2023; 13 (1): 36–45. (in Russian)
42. Roziakova L., Mladosievicova B. Endocrine late effects after hematopoietic stem cell transplantation. Oncol Res. 2010; 18 (11–12): 607–15.
43. Paviglianiti A. Endocrine and metabolic disorders after hematopoietic cell transplantation. Turk J Hematol. 2020; 37 (2): 111–5.
44. McClune B.L., Majhail N.S. Osteoporosis after stem cell transplantation. Curr Osteoporos Rep. 2013; 11 (4): 305–10.
45. Zhang X.F., Ye, L., Hu J. Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient. PLoS One. 2012; 7 (2): e31887.
46. Burt R.K., Balabanov R., Burman J., et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019; 321 (2): 165–74.
47. Burt R.K., Balabanov R., Tavee J., et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2020; 267 (11): 3378–91.
48. Li L., Shen S., Ouyang J., et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 2012; 97 (5): 1729–36.
49. Snarski E., Milczarczyk A., Torosian T., et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 2011; 46 (4): 562–6.
50. Gu W., Hu J., Wang W., Li L., Tang W., Sun S., Cui W., et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care. 2012; 35 (7): 1413–9.